1.Establishment of I-131, Tc-99m labeling methods to in-house anti-CEA antibodies and evaluation of the immunological characteristics.
June Key CHUNG ; Dong Soo LEE ; Myung Chul LEE ; Hong Keun CHUNG ; Chang Soon KOH ; Mee Kyoung HONG ; Seok Rye CHOI ; Il Taek SEO ; Jun Ho CHUNG
Korean Journal of Nuclear Medicine 1992;26(2):346-354
No abstract available.
Antibodies*
2.The frequencies of unexpected antibodies in transfusion candidates and selection of cross-matching method.
Hyun Ok KIM ; Dong Il WON ; Oh Hun KWON
Korean Journal of Blood Transfusion 1993;4(1):35-41
No abstract available.
Antibodies*
3.A Case of Neonatal Lupus Erythematosus Associated with Anti-U1RNP Antibodies.
Byung Hoon AHN ; Gu Chang LEE ; Tae Young YOON ; Mi Jung KIM
Korean Journal of Pediatrics 2005;48(3):342-345
Neonatal lupus erythematosus(NLE) is a distinct subset of lupus characterized by cutaneous findings, cardiac conduction defects, hepatic or hematologic abnormalities. These manifestations are associated with the presence of maternal auto-antibodies such as anti-SSA/Ro, anti-SSB/La, and rarely anti- RNP(U1RNP) antibodies. Cases of U1RNP antibody-positive NLE have somewhat atypical cutaneous manifestation without cardiac or systemic abnormalities. We report a case of cutaneous NLE associated with U1RNP antibodies.
Antibodies*
4.A comparative study of three detection methods for antiplatelet antibodies -ELISA, PSIFT, LCT-.
Hyun Ok KIM ; Jin Ju KIM ; Hyon Suk KIM ; Oh Hun KWON ; Samuel Y LEE
Korean Journal of Blood Transfusion 1991;2(1):11-18
No abstract available.
Antibodies*
5.Special issue on therapeutic antibodies and biopharmaceuticals.
Experimental & Molecular Medicine 2017;49(3):e304-
No abstract available.
Antibodies*
6.Affibody molecules as engineered protein drugs.
Experimental & Molecular Medicine 2017;49(3):e306-
Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man. The small size and ease of engineering make Affibody molecules suitable for use in multispecific constructs where AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease.
Antibodies
8.Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent(R) Technology.
Korean Journal of Hematology 2011;46(3):148-150
No abstract available.
Antibodies
9.A Measurement of Measles Antibodies among the Age Between 6 to 15 Months.
Kyoung Tae HWANG ; Kyu Chong CHOI ; Jong Soo KIM ; Chang Ju CHO ; Baek Keun LIM ; Hyun Sook KIM ; Dong Soo KIM
Journal of the Korean Pediatric Society 1986;29(4):27-32
No abstract available.
Antibodies*
;
Measles*
10.Anti-enteric Neuronal Antibodies and the Irritable Bowel Syndrome: Are They Really the Accused?.
Journal of Neurogastroenterology and Motility 2012;18(2):231-232
No abstract available.
Antibodies
;
Neurons
Result Analysis
Print
Save
E-mail